Advertisement
Screener

ZAI LAB LIMITED (ZLAB) ROE

Zai Lab Ltd ROE

Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Zai Lab Ltd roe for the quarter ending 2026-06-30 was -31.01%, a change of -4.16% year-over-year.
  • Zai Lab Ltd roe for the quarter ending 2026-03-31 was -26.91%, a change of 4.18% year-over-year.
  • Zai Lab Ltd roe for the quarter ending 2025-12-31 was -24.53%, a change of 6.04% year-over-year.
  • Zai Lab Ltd roe for the quarter ending 2025-09-30 was -27.21%, a change of 13.35% year-over-year.
  • Zai Lab Ltd roe for fiscal 2025 was -24.53%, a change of 6.04% from fiscal 2024.
  • Zai Lab Ltd roe for fiscal 2024 was -30.57%, a change of 11.46% from fiscal 2023.
  • Zai Lab Ltd roe for fiscal 2023 was -42.03%, a change of 0.36% from fiscal 2022.
  • Zai Lab Ltd roe for fiscal 2022 was -42.40%, a change of 8.65% from fiscal 2021.
Available history
2015-12-31 to 2026-06-30
Data captured

Historical ROE

DateROENet income 12 monthNet income 3 monthShareholder equity
2026-06-30-31.01%-$188.21M-$50.83M$607.04M
2026-03-31-26.91%-$178.12M-$51.02M$661.98M
2025-12-31-24.53%-$175.54M-$50.37M$715.5M
2025-09-30-27.21%-$206.81M-$35.96M$759.95M
2025-06-30-26.84%-$212.52M-$40.73M$791.74M
2025-03-31-31.09%-$252.07M-$48.44M$810.75M
2024-12-31-30.57%-$257.1M-$81.68M$840.9M
2024-09-30-40.57%-$270.85M-$41.67M$667.67M
2024-06-30-42.37%-$298.33M-$80.28M$704.18M
2024-03-31-44.47%-$338.95M-$53.47M$762.17M
2023-12-31-42.03%-$334.62M-$95.41M$796.12M
2023-09-30-34.16%-$300.96M-$69.15M$880.98M
2023-06-30-42.15%-$393M-$120.89M$932.31M
2023-03-31-40.95%-$410.04M-$49.14M$1B
2022-12-31-42.40%-$443.29M-$61.78M$1.05B
2022-09-30-53.65%-$593.34M-$161.19M$1.11B
2022-06-30-43.60%-$528.56M-$137.93M$1.21B
2022-03-31-42.35%-$553.96M-$82.39M$1.31B
2021-12-31-51.05%-$704.47M-$211.82M$1.38B
2021-09-30-35.84%-$569.19M-$96.41M$1.59B
2021-06-30-32.09%-$536.52M-$163.32M$1.67B
2021-03-31-44.95%-$453.83M-$232.91M$1.01B
2020-12-31-23.00%-$268.91M-$76.55M$1.17B
2020-09-30-20.96%-$238.79M-$63.74M$1.14B
2020-06-30-51.65%-$240.41M-$80.63M$465.47M

Annual ROE

DateROENet income 12 monthShareholder equity
2025-12-31-24.53%-$175.54M$715.5M
2024-12-31-30.57%-$257.1M$840.9M
2023-12-31-42.03%-$334.62M$796.12M
2022-12-31-42.40%-$443.29M$1.05B
2021-12-31-51.05%-$704.47M$1.38B
2020-12-31-23.00%-$268.91M$1.17B
2019-12-31-66.20%-$195.07M$294.66M
2018-12-31-55.39%-$139.08M$251.08M
2017-12-31-21.42%-$50.38M$235.17M
2016-12-3172.77%-$37.51M-$51.55M
2015-12-3198.10%-$18.02M-$18.37M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aurinia Pharmaceuticals Inc. (AUPH)$2.207B7.18
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
OCULAR THERAPEUTIX, INC (OCUL)United States$2.159B-7.15
Viridian Therapeutics, Inc.\DE (VRDN)United States$2.342B-5.38
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Braveheart Bio, Inc. (BRVE)United States$2.106B
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67